Intercept Pharmaceuticals Inc (ICPT) Receives Average Recommendation of “Hold” from Analysts

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been given an average recommendation of “Hold” by the nineteen analysts that are covering the company. Three analysts have rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $176.90.

ICPT has been the topic of several recent research reports. Citigroup Inc set a $240.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 28th. Robert W. Baird reiterated a “positive” rating on shares of Intercept Pharmaceuticals in a research report on Friday, February 10th. BMO Capital Markets lifted their target price on shares of Intercept Pharmaceuticals from $198.00 to $221.00 and gave the stock an “outperform” rating in a research report on Friday, February 24th. Wedbush reiterated an “outperform” rating and set a $224.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, February 16th. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, March 22nd.

COPYRIGHT VIOLATION NOTICE: “Intercept Pharmaceuticals Inc (ICPT) Receives Average Recommendation of “Hold” from Analysts” was originally published by sleekmoney and is the sole property of of sleekmoney. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at http://sleekmoney.com/intercept-pharmaceuticals-inc-icpt-receives-average-recommendation-of-hold-from-analysts/1734134.html.

In other news, insider Lisa Bright sold 254 shares of Intercept Pharmaceuticals stock in a transaction on Monday, February 27th. The shares were sold at an average price of $119.48, for a total value of $30,347.92. Following the completion of the sale, the insider now owns 21,695 shares in the company, valued at approximately $2,592,118.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO David Shapiro sold 346 shares of Intercept Pharmaceuticals stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $115.00, for a total transaction of $39,790.00. Following the completion of the sale, the chief marketing officer now owns 46,023 shares of the company’s stock, valued at approximately $5,292,645. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,124 shares of company stock valued at $129,589. Company insiders own 9.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ICPT. Pacer Advisors Inc. raised its stake in Intercept Pharmaceuticals by 9.5% in the third quarter. Pacer Advisors Inc. now owns 1,384 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 120 shares in the last quarter. Bbva Compass Bancshares Inc. raised its stake in Intercept Pharmaceuticals by 8.4% in the third quarter. Bbva Compass Bancshares Inc. now owns 2,112 shares of the biopharmaceutical company’s stock valued at $348,000 after buying an additional 164 shares in the last quarter. California State Teachers Retirement System raised its stake in Intercept Pharmaceuticals by 0.6% in the third quarter. California State Teachers Retirement System now owns 34,959 shares of the biopharmaceutical company’s stock valued at $5,754,000 after buying an additional 200 shares in the last quarter. National Planning Corp raised its stake in Intercept Pharmaceuticals by 0.4% in the fourth quarter. National Planning Corp now owns 52,720 shares of the biopharmaceutical company’s stock valued at $5,675,000 after buying an additional 210 shares in the last quarter. Finally, Aperio Group LLC raised its stake in Intercept Pharmaceuticals by 13.6% in the third quarter. Aperio Group LLC now owns 2,194 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 263 shares in the last quarter. Institutional investors own 82.28% of the company’s stock.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.29% during midday trading on Monday, reaching $109.02. 254,927 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 52-week low of $96.63 and a 52-week high of $177.93. The stock’s market cap is $2.71 billion. The stock has a 50-day moving average price of $119.81 and a 200-day moving average price of $119.71.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($4.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.74) by $1.10. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The company earned $13 million during the quarter, compared to analyst estimates of $8.96 million. During the same quarter in the previous year, the business posted ($3.62) earnings per share. The company’s revenue for the quarter was up 2966.7% on a year-over-year basis. Analysts forecast that Intercept Pharmaceuticals will post ($16.24) earnings per share for the current year.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/intercept-pharmaceuticals-inc-icpt-receives-average-recommendation-of-hold-from-analysts/1734134.html

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *